摘要
多发性骨髓瘤(multiple myeloma,MM)是一种克隆性浆细胞异常增殖的恶性肿瘤,目前尚未有彻底治愈的方法。大多数患者在接受治疗后仍面临复发或疾病进展的问题。单克隆抗体作为一种新型生物制剂,在新诊断的多发性骨髓瘤(newly diagnosed multiple myeloma,NDMM)及复发/难治性多发性骨髓瘤(relapse/refraactory multiple myeloma,RRMM)患者中显示出显著的疗效,为患者带来了更多的临床获益。本文基于现有的循证医学证据,对单克隆抗体在MM治疗中的应用做一综述。
Multiple myeloma(MM)is a malignant tumor caused by abnormal proliferation of plasma cells,which is currently not fully curable,and most patients will face the problem of recurrence or disease progression after treatment.Monoclonal antibodies,as a novel biological drug,have been proved to have significant therapeutic effects in patients with multiple myeloma,and can bring more clinical benefits to patients.This review summarizes the application of monoclonal antibodies in multiple myeloma based on the existing evidence-based research.
作者
聂珊珊
刘艳
张志瑢
NIE Shanshan;LIU Yan;ZHANG Zhirong(Department of Graduate,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Hematology,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China)
出处
《山东第一医科大学(山东省医学科学院)学报》
2025年第5期266-270,共5页
Journal of Shandong First Medical University & Shandong Academy of Medical Sciences
基金
泰安市科技创新发展计划(政策引导类)(2023NS233)。
